The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

NCT01171768 | Completed

• 1 other identifier: 2008-05-043
• Study Type: observational
• Target: 52
• Locations: 1 country
• Sites: 1

Brief Summary

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.

Conditions

Inflammatory Lung Diseases; Hemoptysis

Keywords

Vascular endothelial growth factor; angiopoietin-2

Outcome Measures

Primary Outcomes (1)

• serum VEGF and Ang-2 level in lung inflammatory disease according to the presence of hemoptysis

  We'll measure the serum VEFG and Ang-2 level of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Comparison of the serum VEGF and Ang-2 level (measured within a week from enrollment) according to the presence of hemoptysis will be primary outcome.

  up to 7 days after enrollment

Secondary Outcomes (1)

• to investigate association between angiogenesis factors and other factors such as inflammatory biomarker and hypoxia.

  up to 7 days after enrollment

Study Arms (2)

patients with hemoptysis within 2 weeks

patients without hemoptysis within 2 years

Eligibility Criteria

• Age: 20 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, peumonia and post-tuberculosis destroyed lung

You may qualify if:

• patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, pneumonia and post-tuberculosis destroyed lung

You may not qualify if:

• patients with tumorous condition including lung cancer, vasculitis and the lung disease associated with collagen vascular disease on the point of enrollment

Sponsors & Collaborators

• Samsung Medical Center: lead

Study Sites (1)

Samsung Medical Center

Seoul, South Korea

Location

MeSH Terms

Conditions

Hemoptysis

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Signs and Symptoms, Respiratory; Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: July 16, 2010
• First Posted: July 28, 2010
• Study Start: June 1, 2008
• Study Completion: December 1, 2010
• Last Updated: July 21, 2011

Record last verified: 2011-07

Locations

KR (1)